Skip to main content Skip to page footer

QIAGEN plans to develop kits for the detection of CALR mutations

Share

Mutations of CALR have been discovered by CeMM recently in an estimated 15% of cases of myeloproliferative neoplasms (MPNs)

Mutations of CALR have been discovered recently in an estimated 15% of cases of myeloproliferative neoplasms (MPNs - a group of blood disorders involving overproduction of blood cells) by the research team of Robert Kralovics at CeMM and collaboration partners at the Medical University of Vienna (NEJM doi: 10.1056/NEJMoa1311347). QIAGEN now licensed the technology from CeMM, and will develop a reliable diagnostic test for the CALR mutations offering each patient a clearer prognostic profile and guiding disease management. Development of a CALR diagnostic test will be highly complementary to QIAGEN’s kits for a key mutation of the Janus kinase 2 (JAK2) gene.